 NEWARK, Calif., Aug. 10, 2021 PRNewswire -- Protagonist Therapeutics, Inc. Nasdaq: PTGX Protagonist or the Company today announced it has resolved its Collaboration Agreement dispute with Zealand Pharma by reducing future development and sales milestone payments and royalties owed to Zealand for Protagonists product candidate rusfertide under the companies 2012 Collaboration Agreement. 